Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer

Author： Méndez M.   Alfonso P.   Pujol E.   González E.   Castañon C.   Cerezuela P.   López-Mateos Y.   Cruz J.  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.23, Iss.3, 2005-06, pp. : 243-251

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

First-Line Treatment Strategies to Improve Survival in Patients with Advanced Colorectal Cancer

By Gill S.  

Drugs, Vol. 64, Iss. 1, 2004-01 ,pp. : 27-44

Adis International

Access to resources Recommend Favorite

Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer

By Yamada Yasuhide  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1690-1696

Springer Publishing Company

Access to resources Recommend Favorite

Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer

By Madajewicz Stefan  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 772-778

Springer Publishing Company

Access to resources Recommend Favorite

Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status

By Kang Myoung  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1607-1613

Springer Publishing Company

Access to resources Recommend Favorite

Irinotecan plus docetaxel a first-line option for NSCLC

By  

Inpharma, Vol. 1, Iss. 1470, 2005-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite